SBFM vs. ASLN, MTEM, GHSI, VIRI, AEZS, ATHE, GRTX, VCNX, CMMB, and MNPR
Should you be buying Sunshine Biopharma stock or one of its competitors? The main competitors of Sunshine Biopharma include ASLAN Pharmaceuticals (ASLN), Molecular Templates (MTEM), Guardion Health Sciences (GHSI), Virios Therapeutics (VIRI), Aeterna Zentaris (AEZS), Alterity Therapeutics (ATHE), Galera Therapeutics (GRTX), Vaccinex (VCNX), Chemomab Therapeutics (CMMB), and Monopar Therapeutics (MNPR). These companies are all part of the "pharmaceutical preparations" industry.
ASLAN Pharmaceuticals (NASDAQ:ASLN) and Sunshine Biopharma (NASDAQ:SBFM) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their risk, institutional ownership, analyst recommendations, media sentiment, earnings, profitability, valuation, dividends and community ranking.
ASLAN Pharmaceuticals received 197 more outperform votes than Sunshine Biopharma when rated by MarketBeat users. However, 100.00% of users gave Sunshine Biopharma an outperform vote while only 63.26% of users gave ASLAN Pharmaceuticals an outperform vote.
ASLAN Pharmaceuticals currently has a consensus target price of $11.33, indicating a potential upside of 2,160.79%. Sunshine Biopharma has a consensus target price of $260.00, indicating a potential upside of 11,058.80%. Given ASLAN Pharmaceuticals' higher probable upside, analysts plainly believe Sunshine Biopharma is more favorable than ASLAN Pharmaceuticals.
58.8% of ASLAN Pharmaceuticals shares are owned by institutional investors. Comparatively, 42.0% of Sunshine Biopharma shares are owned by institutional investors. 4.7% of ASLAN Pharmaceuticals shares are owned by insiders. Comparatively, 14.7% of Sunshine Biopharma shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
ASLAN Pharmaceuticals has a beta of 1.45, meaning that its stock price is 45% more volatile than the S&P 500. Comparatively, Sunshine Biopharma has a beta of 1.17, meaning that its stock price is 17% more volatile than the S&P 500.
In the previous week, ASLAN Pharmaceuticals and ASLAN Pharmaceuticals both had 5 articles in the media. ASLAN Pharmaceuticals' average media sentiment score of -0.17 beat Sunshine Biopharma's score of -0.20 indicating that Sunshine Biopharma is being referred to more favorably in the news media.
Sunshine Biopharma has higher revenue and earnings than ASLAN Pharmaceuticals. ASLAN Pharmaceuticals is trading at a lower price-to-earnings ratio than Sunshine Biopharma, indicating that it is currently the more affordable of the two stocks.
ASLAN Pharmaceuticals has a net margin of 0.00% compared to ASLAN Pharmaceuticals' net margin of -18.70%. ASLAN Pharmaceuticals' return on equity of -21.03% beat Sunshine Biopharma's return on equity.
Summary
Sunshine Biopharma beats ASLAN Pharmaceuticals on 9 of the 16 factors compared between the two stocks.
Get Sunshine Biopharma News Delivered to You Automatically
Sign up to receive the latest news and ratings for SBFM and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding SBFM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Sunshine Biopharma Competitors List
Related Companies and Tools
